Occidental's earnings power is a leveraged bet on West Texas Intermediate; with the stock at $58.71 versus a base IV of $28.46, even a Buffett endorsement does not close a 2.06x gap. This is Too Hard, not because OXY is a bad company, but because owning it requires a forecast we refuse to make.

Plain English

Occidental pumps oil and sells chemicals. It makes a lot of money when oil is expensive and very little when oil is cheap. Nobody — not the CEO, not Buffett, not us — can reliably tell you what oil will cost in five years. The stock today costs about twice what our model says the company is worth, even before that uncertainty. Buffett owns a big piece because he got special terms we cannot get. For everyone else, this is a bet on the oil price wearing the costume of a company. Buffett-Munger investing skips bets like that.

Thesis

Occidental Petroleum is a Permian-weighted integrated oil and gas producer with a chemicals arm (OxyChem, being sold to Berkshire per the 2025 letter [5]) and a nascent carbon-capture business. Berkshire owns 27.8% plus warrants [1], which lends a halo to the name but does not, in itself, constitute a thesis.

The scorecard tells a coherent story. Composite is 56/100. Profitability is 15: ROIC 10-year average is 0.0% and the scorer flagged that NOPAT declined and ROIIC is not meaningful. Balance sheet is 17 with net-debt-to-EBITDA at 2.80x post the CrownRock acquisition. Capital allocation is 15: share count is up 2.66% over ten years and FCF conversion is 2.13x. Valuation is the killer line: 9. The stock at $58.71 trades at 24.06x TTM earnings versus a 10-year average of 19.29x, EV/FCF of 14.72x, and a reverse-DCF that requires 5.14% perpetual growth to justify the print. Owner earnings TTM are $2.24B; IV base is $28.46 and IV high is $36.19. Price-to-IV is 2.06x.

The right thesis on OXY is not at $58. It is at the price where the developed reserves alone underwrite the equity. Per Damodaran, commodity firms derive value from developed reserves plus the option value of undeveloped reserves, and that option is a function of oil-price volatility, not just the spot price [3][4]. We do not forecast oil. So even before getting to moat or management, we have a price problem we cannot reason past. Owning OXY at a 2x premium to base IV with a 0% 10-year ROIC is a bet on a commodity cycle, not a compounder.

Moat

Brief note (Too Hard verdict): OXY's edge is geological and operational, not structural. Tier-one Permian acreage post-CrownRock plus Anadarko's legacy basins gives a low-cost-quartile position relative to higher-cost shale, and OxyChem is a competent commodity-chemicals business [5]. Carbon capture is a strategic option but Buffett himself notes that the economic feasibility 'has yet to be proven' [1]. None of this constitutes a Buffett-style moat: the unit of sale is a barrel of oil at the global market price, the customer is fungible, and the competitor stress test ($10B + 5 years) is irrelevant because OPEC, US shale aggregate, and macro demand set the price, not OXY. Pricing power: none. Switching costs: none. Network effects: none. Intangibles: none beyond ordinary trade reputation. Cost advantage: real but narrow and basin-dependent. Moat verdict: NARROW.

Management

Brief note (Too Hard verdict): Vicki Hollub's record is a study in two halves. The 2019 Anadarko deal was levered, expensive, and required Buffett-financed preferreds at 8% plus warrants; it nearly broke the company in the 2020 collapse. Since then management has paid down debt aggressively, restored the dividend, and bought back the Berkshire preferred at par. The 2024 CrownRock acquisition (~$12B) re-levered the balance sheet to 2.80x net-debt-to-EBITDA, justifiable on Permian inventory grounds but pro-cyclical in timing. Share count is up 2.66% over ten years (scorecard) — meaning net buybacks have not offset issuance and acquisition currency. FCF conversion at 2.13x looks strong but is partly a function of working-capital and tax timing in the TTM window. Selling OxyChem to Berkshire [5] is a capital-allocation positive: it monetizes a non-core asset to a price-disciplined buyer and de-levers. Buffett's continued endorsement and warrant ownership [1] is a meaningful character vote. But character does not change the underlying math: a CEO of a commodity producer is largely a price-taker, and capital allocation in the up-cycle has been more re-investment and acquisition than disciplined buybacks at low prices. Capital allocator: B.

Industry

Brief note (Too Hard verdict): The integrated upstream oil and gas industry is a textbook Porter-bad business. Rivalry: intense and global, with OPEC+ as a swing producer and US shale as a marginal-cost setter. Buyer power: high — refiners and traders price off Brent/WTI benchmarks; producers are price-takers. Supplier power: moderate — oilfield services concentrate (SLB, HAL, BKR) and frac sand/labor cycle with activity. Threat of substitutes: structurally rising — EVs, renewables, efficiency, and policy compress long-run demand even if near-term volumes hold. Threat of entry: low at the major level (capital intensity), high at the basin level (any private E&P with capital can drill the Permian). Value pool location: tier-one Permian acreage, midstream takeaway, and integrated chemicals. Trajectory: the value pool is migrating to the lowest-cost barrel and to operators with carbon-management optionality, but the absolute size of the pool depends on a price we cannot predict [3]. The Damodaran framing is precise: commodity-company value is a function of price AND volatility, with undeveloped reserves trading as call options [3][4]. Industry Verdict: Poor.

Inversion

The bear case writes itself, and writing it is the cleanest way to see why this is Too Hard rather than a Buy.

The single event that kills this. A WTI print in the high $40s for two-plus quarters. CrownRock economics were underwritten at strip prices materially above that. Net-debt-to-EBITDA at 2.80x today becomes 4x+ in a $50 world as EBITDA compresses faster than debt amortizes. The dividend gets re-cut, the buyback stops, capex is throttled, and the equity re-rates from a growth-cyclical to a distressed-cyclical multiple. This is not speculative — it is the 2020 movie with a different opening scene.

Why the moat is narrower than bulls think. Permian tier-one inventory is finite and the best rock is being drilled now. Every operator in the basin claims a decade-plus of inventory; the geology says the best zones are being high-graded into 2026-2028 and parent-child interference is real. OxyChem is a fine business but is being sold [5], so the bull's 'integrated cushion' argument is about to disappear from the consolidated cash flow. Carbon capture is, per Buffett himself, of unproven economics [1] — a moonshot, not a moat.

Why management is worse than it appears. Hollub has done two large levered acquisitions (Anadarko 2019, CrownRock 2024) at or near cycle highs. Both required Berkshire as a financing partner or backstop in spirit. The pattern is: lever up in the boom, deleverage in the bust, repeat. That is not bad management for a cyclical, but it is the opposite of the Buffett-Munger ideal of buying back stock at low prices and sitting on cash at high ones. Share count up 2.66% over ten years confirms the picture — net dilution, not accretion.

What bulls are extrapolating that won't hold. Three things. First, that $70-80 WTI is the new normal because of OPEC+ discipline and US shale exhaustion. Cycles always feel structural at the top. Second, that Berkshire's stake is a put — it is not; Berkshire has explicitly stated it has 'no interest in purchasing or managing Occidental' [1]. Third, that the 24.06x TTM P/E is justified by 'normalized' earnings — but normalized earnings for a price-taker are by definition a function of normalized commodity prices, which the analyst is implicitly assuming favorable.

Valuation trap (multiple compression / regime change). Reverse DCF at $58.71 implies 5.14% perpetual growth in owner earnings. For a depleting-asset business in a flat-to-declining demand industry, that requires either (a) sustained $80+ WTI, (b) volume growth that contradicts depletion math, or (c) margin expansion against a rising service-cost base. None is base case. The IV range — low $28.37, base $28.46, high $36.19 — already reflects a 'widen the band' adjustment for maintenance-capex uncertainty in the scorer notes. Even at the high IV of $36.19, the stock is 62% above intrinsic value. The compression path: any cycle softening drops the multiple from 24x to a 10-year-low 8-10x trailing as earnings compress simultaneously, a classic cyclical double-whammy. The Damodaran 1984 Gulf Oil framing is the historical analog: an LBO at $70 against an option-adjusted IV of $51 looked aggressive then and the math has not changed [4].

If I am right, the stock could be worth $30 within 3 years.

Lollapalooza Bias Check

Authority bias is the loudest active force right now. Berkshire owns 27.8% of OXY plus warrants [1], and Buffett has written warmly about the company's strategic importance to US energy security. The temptation is to read 'Buffett owns it' as 'I should own it,' which is exactly the social-proof shortcut Munger warns against. The cure is to remember that Buffett bought via preferred-stock financing in 2019 with an 8% coupon and warrants — economics no public-market buyer at $58.71 will ever see — and that he has explicitly said Berkshire has 'no interest in purchasing or managing Occidental' [1].

Recency bias is also active. The 2022-2024 period of $80+ WTI, sanctions-driven supply shocks, and OPEC+ discipline has trained investors to view higher prices as the steady state. The scorecard's reverse-DCF implied growth of 5.14% bakes in some of that recency.

Anchoring is present in two places: anchoring to the 52-week range (the stock has been higher, so $58 'feels cheap'), and anchoring to nominal P/E of 24x as if it were a stable-business multiple. For a cyclical at peak earnings, P/E is upside down — high P/E at trough earnings is normal, low P/E at peak earnings is the trap.

Confirmation bias would be active if I went looking for reasons OXY is cheap; I have to actively look for the bear evidence, which the inversion section forces.

Incentive bias affects how I read management commentary: Hollub's compensation rewards production growth and acquisition execution, not per-share intrinsic value. I have to discount forward-looking statements accordingly. The honest read: at a 2.06x price-to-base-IV ratio, no reframing of the qualitative case rescues the math.

10-Year Outlook

Fundamental business model in 10 years: yes, OXY will still pump oil, sell chemicals (or have sold OxyChem), and run carbon-capture pilots. But that is the wrong question for a commodity. The right question is: will the per-barrel economics ten years out be predictable enough to underwrite a price today? No. Long-run oil demand is contested between IEA scenarios that range from 80mbpd to 110mbpd in 2035 depending on EV adoption, policy, and Asian growth. That uncertainty is too wide to be priced.

Customer base larger? Customers are refiners and traders pricing off benchmarks; size of base is irrelevant — only price matters. Profit per customer higher? Unknown and uncontrollable; depends on WTI minus lifting cost. Moat wider? No structural reason to expect it. Permian inventory is being depleted, not grown; OxyChem is being divested. Carbon capture might become an earnings line if 45Q credits expand, but Buffett's own 'economic feasibility yet to be proven' [1] is the right framing.

Single biggest threat: a sustained sub-$60 WTI environment driven by EV penetration outpacing depletion. Secondary threat: regulatory or tax regime change on US shale (mineral royalties, methane rules, federal-land permitting).

The Buffett-Munger 10-year test is not 'will this company exist' — it is 'can I confidently say its owner earnings will be higher and the moat wider.' For OXY, the answer is unknowable in any rigorous sense. That is the definition of outside the circle of competence.

CONFIDENCE: low

Position Guidance

• Recommendation: Too Hard
• Conviction: high (in the Too Hard verdict, not in a directional call)
• Target buy price: $25 — at or below base IV of $28.46, with a margin of safety for commodity-price uncertainty and the 0% 10-year ROIC. Even at this price, position only if oil-price thesis is independently held.
• Target trim price: $40 — above the high IV of $36.19; existing holders should consider trimming materially above this level.
• Position sizing: 0% in a Buffett-Munger book. If held for non-Compounder reasons (energy-sector exposure, inflation hedge), cap at 2% and treat as a trade, not a compounder.
• Why Too Hard: Commodity price is the dominant value driver and is explicitly outside Munger's circle-of-competence filter. Price/IV of 2.06x removes any margin of safety. Berkshire's 27.8% stake [1] does not change the math for a public-market buyer at $58.71.